Navigation Links
Phase II Trial of Experimental Anti-Coagulant Reports Safety and Outcomes Data
Date:11/11/2008

e most commonly used anticoagulant, or anti-clotting medication, works on several aspects of the clotting process, including Factor X. Compared to rivaroxaban, warfarin seems to be slower to reach therapeutically effective levels in the body and it requires repeated blood testing of patients who take it, beginning with tests to ensure that the therapy has achieved the goal of reduced clotting speed, Gibson said. This is important because if their blood clots too quickly, it could lead to a stroke or heart attack; if it clots too slowly that could lead to bleeding, he explained.

The ATLAS ACS-TIMI 46 Trial is more than twice the size of the second-largest study. That study, APPRAISE, found a non-significant trend toward benefits and a clear dose-response with more bleeding events at higher doses, he said.

A Phase III trial, expected to enroll 16,000 patients randomized to twice a day doses of 2.5 mg or 5 mg of rivaroxaban for six months is expected to begin in December 2008.

Co-authors include Jessica L. Mega, M.D.; Christopher J. Hammett M.D.; Vasil Hricak M.D.; Pascual Bordes M.D.; Adam Witkowski M.D.; Valentin Markov M.D.; Paul Burton M.D.; and Eugene Braunwald M.D. who chaired the study. Individual author disclosures can be found on the abstract.

The study was sponsored by Bayer AG, Leverkusen, Germany and Johnson & Johnson Pharmaceutical Research & Development, Raritan, N.J.

Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict pol
'/>"/>

SOURCE American Heart Association
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder
2. Ceregene Phase 2 Clinical Trial for Alzheimers Disease to be Funded by $5.4 Million Grant From National Institutes of Health
3. Derma Sciences Enrolls First Patient in DSC127 Phase II Study
4. Morria Biopharmaceuticals Plc Announces Preliminary Results Regarding Inflammatory Markers From its Phase II Study in Allergic Rhinitis
5. Phase 2a Data for MEDI-528 Presented at CHEST 2008
6. Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study
7. BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
8. QLT announces encouraging Phase II data from core study of Punctal Plug Drug Delivery System
9. Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two
10. Teksouth Awarded $100,000 Defense Department Grant in First Phase of Medical Data Integration Project
11. Assessing the quality of phase I clinical trial abstracts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... The second episode of “Extreme Weight Loss” Season ... need to transform their lives. Josh (29 years old) is ... deal with the death of his father. Kelli (26 years ... MO, who went into depression after her playing career ended. ... featured in one episode of “Extreme Weight Loss” on TUESDAY, ...
(Date:5/27/2015)... NJ (PRWEB) May 28, 2015 Throughout the ... study site for research comparing the validity and reliability of ... Dr. Preeti Nair, P.T., Ph.D., Associate Professor in the Department ... investigator for the study. , The Shaw Gait Assessment is ... piece of equipment. The GaitRite is considered the gold ...
(Date:5/27/2015)... Thermage was the first to come out ... in 2007 coinciding with the release of NXT or CPT, ... Precision Aesthetics was the first practice in New York to ... produced results that had never been achieved before non-surgically. ... still considered by many as the leading skin tightening device. ...
(Date:5/27/2015)... Ticket Down is a reputable source of 2015 ... currently in the middle of their series against the Anaheim Ducks ... If the Blackhawks can win tonight at home, this will tie ... 30th at the Honda Center in Anaheim. , During the ... Western Conference as they won the Pacific Division by 8 points ...
(Date:5/27/2015)... Ticket Down is a reputable source for 2015 Cleveland Cavaliers ... during the 2014-15 NBA season and they delighted their fan base ... of 118-88. , For the Cavaliers, this is their ... lost to the San Antonio Spurs. Once Lebron James joined ... it to the NBA finals increased tenfold. The team had ...
Breaking Medicine News(10 mins):Health News:“Extreme Weight Loss”: Josh and Kelli’s Journeys Begin at the University of Colorado Anschutz Health and Wellness Center 2Health News:“Extreme Weight Loss”: Josh and Kelli’s Journeys Begin at the University of Colorado Anschutz Health and Wellness Center 3Health News:Push to Walk Partners with Seton Hall University for Study 2Health News:Non-Surgical Fat Reduction and Skin Tightening Procedures, Thermage and Exilis, Increase 200% at Precision Aesthetics in New York, April 2015 2Health News:Blackhawks vs. Ducks NHL Western Conference Finals Tickets: Ticket Down Slashes Ticket Prices on Chicago Blackhawks vs. Anaheim Ducks 2015 NHL Western Conference Finals 2Health News:Cavs NBA Finals Tickets: Ticket Down Slashes Ticket Prices on Cleveland Cavaliers 2015 NBA Finals Tickets at Quicken Loans Arena and Offers Valuable Promo Code 2
... could boost death risk, researchers say , , TUESDAY, ... men at high risk for cardiovascular disease, diabetes and ... the odds, according to new studies. , Some ... common with age, are linked to several health conditions. ...
... to the public, agency says , , TUESDAY, June 17 (HealthDay ... letters warning more than two dozen companies to stop selling ... The agency is also cautioning consumers not to buy or ... and creams, and are sold under various names on the ...
... Labs That Are Looking to Place Strategic Bets for the ... ... /Xinhua-PRNewswire/ -- Singapore,s investment of,more than US$2.1 billion in the biomedical sciences ... spending in the,biomedical sciences grew by more than 24% to reach US$760 ...
... Many Have Changed to Health Care & Economic Security ... SPRINGFIELD, Ill., June 17 150 years ago,this ... the,Illinois State Capitol in Springfield. AARP Illinois took the ... issues have changed,the problems of division preventing progress on ...
... Health,Insurance Plans (AHIP) today announced a new ... information technology company, to assist,health insurance plans ... consumers., "This partnership reflects our industry,s ... Health Records," said Charles,Stellar, Executive Vice President ...
... Health,Services, Inc. (Nasdaq: GTIV ), the nation,s leading ... is scheduled to,present from 1:00 to 1:30 p.m. ET, ... Conference in New York., The presentation will be ... which may be accessed by visiting, http://investors.gentiva.com/events.cfm to ...
Cached Medicine News:Health News:Studies Support Testosterone Supplements for Older Men 2Health News:FDA Warns Companies to Stop Selling Fake Cancer Cures 2Health News:FDA Warns Companies to Stop Selling Fake Cancer Cures 3Health News:Singapore Is One of the Fastest Growing Bioclusters in Asia; Wave of Investments in Drug Discovery and Translational Research 2Health News:Singapore Is One of the Fastest Growing Bioclusters in Asia; Wave of Investments in Drug Discovery and Translational Research 3Health News:Singapore Is One of the Fastest Growing Bioclusters in Asia; Wave of Investments in Drug Discovery and Translational Research 4Health News:Singapore Is One of the Fastest Growing Bioclusters in Asia; Wave of Investments in Drug Discovery and Translational Research 5Health News:Singapore Is One of the Fastest Growing Bioclusters in Asia; Wave of Investments in Drug Discovery and Translational Research 6Health News:150 Years Later 'House Divided' Speech Still Holds Strong Message 2Health News:AHIP Selects HealthTrio to Join AHIP Solutions Program 2Health News:Gentiva(R) Health Services to Present June 24 at Jefferies' 2nd Annual Healthcare Conference in New York 2Health News:Gentiva(R) Health Services to Present June 24 at Jefferies' 2nd Annual Healthcare Conference in New York 3
(Date:5/27/2015)... 2015 OpportunityAnalyzer: Cushing,s Syndrome - Opportunity ... GlobalData estimates that the 2013 sales for the ... across the 6MM covered in this report. Pharmaceutical ... time, and financial resources in the CS field, ... (R&D) strategies. One notable example is the fact ...
(Date:5/27/2015)... May 27, 2015 ... has announced the addition of the  "2015 ... Market"  report to their offering. ... issues pertaining to the US NAT laboratory ... demographic, social and technological trends with significant ...
(Date:5/27/2015)... Research and Markets ( ... the  "US Cancer Vaccine Market Outlook 2020" ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ,Cancer vaccines ... categories of prophylactic (preventive) and therapeutic (treatment) ... both of these groups have been marketed ...
Breaking Medicine Technology:OpportunityAnalyzer: Cushing's Syndrome - Opportunity Analysis and Forecasts to 2018 2OpportunityAnalyzer: Cushing's Syndrome - Opportunity Analysis and Forecasts to 2018 3OpportunityAnalyzer: Cushing's Syndrome - Opportunity Analysis and Forecasts to 2018 4United States Nucleic Acid Testing Market Strategies 2015-2020 2US Cancer Vaccine Market Outlook 2020 2US Cancer Vaccine Market Outlook 2020 3
... - Termination of Parkinson,s Disease Clinical Development and Focus ... Neuropathic Pain and Epilepsy ... is a first-in-class,orally administered, highly selective non-competitive AMPA-type glutamate,receptor ... disease, neuropathic pain, epilepsy, multiple,sclerosis and migraine prophylaxis., ...
... Napo,Pharmaceuticals, Inc., (LSE: NAPL and NAPU) is pleased ... Phase 2 trial for CRO-ID,(crofelemer for the treatment ... Glenmark Pharmaceuticals Limited (BSE: Glenmark). The,primary endpoints of ... frequency and stool consistency; additional endpoints followed,include degree ...
Cached Medicine Technology:Status of the E2007 (perampanel) Development Program 2Status of the E2007 (perampanel) Development Program 3Status of the E2007 (perampanel) Development Program 4Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea 2Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea 3Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea 4Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea 5
...
...
...
Tip is bent towards port for downward irrigation. 25G x 5/8in (.50 x 22mm)...
Medicine Products: